ArvinYangMD

Physician

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2008
Rutgers Robert Wood Johnson Medical SchoolClass of 2005

PubMed

2013 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phas...
Jeffrey S. Weber, Sandra P. D'Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer
The Lancet. Oncology. 2015-04-01
132 citations
Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Arvin S. Yang, Edmund C. Lattime
Cancer Research. 2003-05-01
50 citations
A Blueprint to Advance Colorectal Cancer Immunotherapies.
Dung T. Le, Vanessa M Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer
Cancer Immunology Research. 2017-11-01

Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. As Senior Vice President and Chief Medical OfficerNovember 30th, 2020
Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (Nivolumab) and Yervoy (Ipilimumab)September 28th, 2019
Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data ShowsNovember 27th, 2018
Join now to see all